Central nervous system disorders include diseases with millions of patients (such as schizophrenia, Alzheimer’s and depression), and they also include rare diseases, such as SMA (spinal muscular atrophy), Friedreich Ataxia, and ALS (amyotrophic lateral sclerosis). Many CNS diseases have no treatments or unsatisfactory treatments, and many of them place a tremendous burden on families and society because they result in a “loss of self.”

In  the second Pullan’s Pieces webinar , business development consultant,  Linda M. Pullan, Ph.D. , builds on the Pullan’s Pieces newsletter infographics and presents an overview of the current CNS drug market landscape and how it compares to other therapeutic areas. She also talks about the top companies and top drugs, new indications, and trends in VC, M&A, and licensing deals in the CNS space.

During the webinar, Linda discusses:  

• What does the current CNS market look like?
• What are the unmet needs?
• Who are the major players?
• What’s in the pipeline?
• What are the deals like?
• What’s coming in the next few years?
• And more...